4
Cash generation from Operations continued to remain favourable this year and is in line with
business performance. Your Company continues to look for ways and means of deploying
accumulated cash balances which remain invested largely in bank deposits.
Your Company has not accepted any fixed deposits during the year. There was no outstanding
towards unclaimed deposit payable to depositors as on 31
st
December 2013.
(b) Pharmaceuticals Business performance and outlook
Your Company continues to enjoy a leadership position in the therapy areas in which it
provides health care solutions to patients.
Your Company has strategically decided to expand its presence in the Specialty segment six
years back. The initiative continues to reflect in its outcome. The growing trend from Specialty
contribution to Sales continued in 2013 and has reached 23%.
Your Company’s leadership in the therapeutic area of Dermatology has been maintained.
In clinical dermatology, most of the steroid products like Betnovate N, Betnovate C, T Bact,
Tenovate and the cosmetology products like Ansolar and Oilatum sustained market competitive
growth, thereby benefiting increased number of patients.
Your Company’s Oncology division’s vision to improve patient care in cancer management by
offering access to breakthrough medicine from GSK’s pipeline at an affordable price (Tiered
Pricing Policy) has benefited almost six thousand patients with our range of products – Tykerb,
Hycamtin, Revolade & Votrient in 2013. Your Company has also initiated two patient support
and management programs “Swasti” for Tykerb and Votrient to enhance patients access.
Patient care is the basic mantra of Oncology and the mission has reflected in its competitive
performance, ranked as the 6
th
largest MNC in Oncology segment (source: IPSOS MAT
JUNE 13). In June 2013, your Company has launched XGEVA licensed from Amgen, USA
for the prevention of SRE (Skeletal Related Events) in the management of bone metastasised
solid tumors. The XGEVA launch has helped treat more than one thousand patients within
six months of its introduction. Oncology division’s ability to differentiate from competition
has reflected in an independent survey conducted by McCANN Health & GFK in the
Asia Pacific Region which rated your Company as the number one company to provide
medical education to Health Care Providers especially, Oncologists, Diabetologists and
Consulting Physicians.
Your Company’s Cardio Vascular presence was strengthen by launching “Cardio Check”
in the diagnostics segment. The device helps establish the patient’s lipid profile in a few
minutes. The point of care addresses the unmet need of the physician to diagnose the lipid
profile in the Doctor’s clinic itself to improve the patient outcome. This strategic expansion is
aimed at improving the Company’s equity among the physicians in the cardiology segment.
This will help your Company to leverage for its existing range of products.
The revitalised Respiratory division focus has become strong with the launch of a dose counter
supported Seretide Evohaler. The new product has achieved 5% of the market share in the
SFC Inhaler segment in 2013. Your Company’s recently launched CNS division has begun
making its impact with Lamictal becoming the 3
rd
largest prescribed Lamotrogine in treating
Anti Epileptic Disease as per SMSRC Prescription Track.
The Mass Speciality business saw constraints on Augmentin on account of limitations at
the site of the overseas supplier. Limitations of supply from a local contract manufacturer
impacted the antibiotic Ceftum in the first half of the year. Sustained and focused efforts have
helped the Mass Speciality business record a market competitive growth in the prescriber
base resulting in benefits to a larger pool of patients.
Market competitive growth has helped some dosage forms of Augmentin to record
significant gain in share, thereby benefiting a much larger patient pool. To help patients with
hypothyrodism, two additional put ups of Eltroxin were launched and were well received
by patients and prescribers. A focused campaign to increase awareness of congenital
hypothyroidism has helped increase disease awareness and resulted in early treatment of
patients, thereby enabling better patient outcomes.
